Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T08:46:57.977Z Has data issue: false hasContentIssue false
  • English
  • Français

Sickle Cell Disease: Primary Stroke Prevention

Published online by Cambridge University Press:  07 November 2014

Mehari Gebreyohanns  and
Robert J. Adams
Get access Rights & Permissions [Opens in a new window]

Abstract

Stroke is an important and common complication of sickle cell disease (SCD), affecting children as well as adults. Clinically evident stroke, usually brain infarction, is usually associated with stenosis or occlusion of the intracranial arteries of the Circle of Willis, sometimes with formation of moyamoya (a Japanese word for “hazy” or “like a puff of smoke” that describes the appearance of a abnormal microvasculature on angiography believed secondary to internal carotid artery stenosis or occlusion and the resultant extensive collateralization). Several types of intracranial hemorrhage are observed but usually in older children and adults. Cerebrovascular diseases restricted to small vessels may go unrecognized but is associated with cognitive and learning problems. Prevention of recurrent stroke has been accomplished with chronic blood transfusion. A primary prevention strategy for clinical stroke, based on the Stroke Prevention in Sickle Cell Anemia Trial, has been tested in a randomized clinical trial. Over 2,000 young children with SCD were screened with transcranial Doppler ultrasound (TCD) to detect elevated blood flow velocity indicative of vessel disease and high risk of future stroke. Those randomized to standard care (no transfusion) had a 10%/year risk of stroke, which was reduced >90% with chronic transfusion. This approach is the only primary stroke prevention strategy so far tested in SCD in a randomized controlled trial. Silent lesions on magnetic resonance imaging are associated with an ∼1.5%/year risk of clinical stroke and a trial is now starting in children with these lesions who do not meet Stroke Prevention in Sickle Cell Anemia Trial criteria for transfusion based on TCD. A controlled trial, based on intervention for nocturnal hypoxemia, is also underway. Hydroxyurea, bone marrow transplantation, antiplatelet, and antithrombotic agents may work but have not been tested in primary prevention in a systematic way. If early and repeated, TCD screening of children, as recommended by National Heart Lung and Blood Institute and the American Stroke Association, were implemented broadly the incidence of new strokes could be greatly reduced in these children.

Type
Review Articles
Information
CNS Spectrums , Volume 9 , Issue 6 , June 2004 , pp. 445 - 449
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCE

1.Ohene-Frempong, K, Weiner, SJ, Sleeper, LA, et al.Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.Google ScholarPubMed
2.Adams, RJ. Neurological complications. In: Embury, SH, Hebbel, RP, Narla, M, Steinberg, MH, eds. Sickle Cell Disease: Scientific Principles and Clinical Practice. New York, NY: Raven Press; 1994:599–621.Google Scholar
3.Armstrong, FD, Thompson, RJ, Wang, W, et al.Cognitive functioning and brain MRI in children with sickle cell disease. Pediatrics. 1996;97:864–870.CrossRefGoogle ScholarPubMed
4.Adams, RJ, Brambilla, DJ, McKie, VC, et al.Transfusion prevents first stroke in children with sickle cell disease: the “STOP” Study. N Engl J Med. 1998;339:5–11.CrossRefGoogle Scholar
5.Weatheall, DJ. The molecular basis of phenotypic diversity in genetic disease. Ann NY Acad Sci. 1995;758;245–260.CrossRefGoogle Scholar
6.Steinberg, ML, Rodgers, GP. Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin Hematol. 2001;38:299–306.CrossRefGoogle ScholarPubMed
7.Russell, MO, Goldgerg, HI, Hodson, A, Kim, HW, Halus, J, Schwartz, E. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984:162–169.Google ScholarPubMed
8.Pavlakis, SG, Prohovnk, , Piomelli, S, DeVivo, DC. Neurological complications of sickle cell disease. Adv Pediatr. 1989;36:247–276.CrossRefGoogle ScholarPubMed
9.Steinberg, ML, Brugnara, C. Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med. 2003;54:89–112.CrossRefGoogle ScholarPubMed
10.Adams, RJ, Nichols, FT, McKie, V, et al.Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology. 1988;38:1012–1017.CrossRefGoogle ScholarPubMed
11.Koshy, M, Thomas, C, Goodwin, J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys. 1990;1:71–78.Google ScholarPubMed
12.Prengler, M, Pavlakis, SG, Prohovnik, I, Adams, RJ. Sickle cell disease: the neurological complications. Ann Neurol. 2002;51:543–552.CrossRefGoogle ScholarPubMed
13.Kinney, TR, Sleeper, LA, Wang, WC, et al.Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640–645.CrossRefGoogle ScholarPubMed
14.Pegelow, CH, Adams, RJ, McKie, V, et al.Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions, J Pediatr. 1995;126:896–899.CrossRefGoogle ScholarPubMed
15. Clinical Alert from the National Heart, Lung, and Blood Institute, Dept. of Health & Human Services. 18 Sept 1997.Google Scholar
16.Adams, RJ, McKie, VC, Nichols, FT, et al.The use of transcranial ultrasonography to ptedict stroke in sickle cell disease. N Engl J Med. 1992;326:605–610.CrossRefGoogle ScholarPubMed
17.Adams, RJ, McKie, VC, Carl, EM, et al.Long term stroke risk in children with sickle cell disease screened with transcranial Doppier. Ann Neurol. 1997;42:699–704.CrossRefGoogle Scholar
18.Adams, RJ, McKie, VC, Brambilla, DJ, et al.Stroke Prevention Trial in Sickle Cell Anemia (“STOP”): study design. Control Clin Trials. 1997:19:110–129.CrossRefGoogle Scholar
19.Vichinsky, EP, Luban, NL, Wright, E, et al.Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41:1086–1092.CrossRefGoogle Scholar
20.Pegelow, CH, Wang, W, Granger, S, et al.Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol. 2001;58:2017–2021.CrossRefGoogle ScholarPubMed
21.Abboud, M, Curé, J, Gallagher, D, et al. magnetic resonance angiography (MRA) in children with abnormal transcranial Doppler (TCD) velocities in the STOP study. Epub 2003 Dec 18.Google Scholar
22.Seibert, JJ, Glasier, CM, Kirby, RS, et al.Transcranial Doppler, MRA, and MRI as a screening examination for cerebrovascular disease in patients with sickle cell anemia: an 8-year study. Pediatr Radiol. 1998;28:138–142.CrossRefGoogle ScholarPubMed
23.Verlhac, S, Bernaudin, F, Tortrat, D, et al.Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. Pediatr Radiol. 1995;25(suppl 1):S14–S19.CrossRefGoogle ScholarPubMed
24.Adams, RJ, Nichols, FT, Figueroa, R, et al.Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke. 1992;23:1073–1077.CrossRefGoogle ScholarPubMed
25.Goldstein, LB, Adams, RJ, Becker, K, et al.Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280–299.CrossRefGoogle ScholarPubMed
26.Miller, ST, Wright, E, Abboud, M, et al.Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr. 2001:139;6:785–789.CrossRefGoogle Scholar
27.Miller, ST, Macklin, EA, Pegelow, CH, et al.The Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139:385–90.CrossRefGoogle ScholarPubMed
28.Charache, S, Terrin, ML, Moore, RD, et al.Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med. 1995;332:1317–1322.CrossRefGoogle ScholarPubMed
29.Ware, RE, Zimmerman, SA, Schultz, WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94:3022–3026.CrossRefGoogle ScholarPubMed
30.Walters, MC, Storb, R, Patience, M, et al.Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood. 2000;95:1918–1924.Google ScholarPubMed
31.Kirkham, FJ, Hewes, DKM, Prengler, M, Wade, A, Lane, R, Evans, JPM. Nocturnal hyposaemia and central-nervous-system events in sickle-cell disease. Lancet. 2001;357:1656–59.CrossRefGoogle ScholarPubMed
32.Adams, RJ, Pavlakis, S, Roach, ES. Sickle cell disease and stroke: primary prevention and transcranial Doppler. Ann Neurol. 2003;54:559–563.CrossRefGoogle ScholarPubMed